Immunogenicity and reactogenicity of two diphtheria-tetanus-whole cell pertussis vaccines in Iranian pre-school children, a randomized controlled trial

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 6, 2013, Pages 1316-1322

  Zarei, Saeed ^a   Jeddi Tehrani, Mahmood ^a   Akhondi, Mohammad Mehdi ^a   Zeraati, Hojjat ^b   Ferydonfar, Amir Ali ^c   Nasernia, Jalaledin ^c   Tavangar, Banafsheh ^a   Shokri, Fazel ^a,b  

^a AVICENNA RESEARCH INSTITUTE   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diphtheria tetanus pertussis vaccine; Enzyme linked immunosorbent assay; Immunogenicity; Randomized controlled trial; Reactogenicity; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ANOREXIA; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BLOOD SAMPLING; CHILD; CHILD HEALTH CARE; CONTROLLED STUDY; DIPHTHERIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; ECZEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; IRAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PERTUSSIS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REACTOGENICITY; TETANUS; VACCINATION; VACCINATION REACTION; VOMITING;

DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; RANDOMIZED CONTROLLED TRIAL; REACTOGENICITY; VACCINATION;

ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMANS; IRAN; MALE; PAIN; PROSPECTIVE STUDIES;

EID: 84880664283     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24093     Document Type: Article

References (24)

1. Pichichero ME, Green JL, Francis AB, Marsocci SM, Lynd AM, Litteer T. Comparison of a three-component acellular pertussis vaccine with whole cell pertussis vaccine in two-month-old children. Pediatr Infect Dis J 1994; 13:193-6; PMID:8177626; http://dx.doi.org/10.1097/00006454-199403000-00005.
2. Rieber N, Graf A, Hartl D, Urschel S, Belohradsky BH, Liese J. Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response. PLoS One 2011; 6:e17271; PMID:21408149; http://dx.doi.org/10.1371/ journal.pone.0017271.
3. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet 2006; 367:1926-36; PMID:16765762; http://dx.doi.org/10.1016/S0140-6736(06)68848-X.
4. von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002; 2:744-50; PMID:12467690; http://dx.doi.org/10.1016/S1473-3099(02)00452-8.
5. Campins-Martí M, Cheng HK, Forsyth K, Guiso N, Halperin S, Huang LM, et al.; International Consensus Group on Pertussis Immunisation. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 2001; 20:641-6; PMID:11738728; http://dx.doi.org/10.1016/S0264-410X(01)00393-0.
6. Tetanus vaccine. Wkly Epidemiol Rec 2006; 81:198-208; PMID:16710950.
7. Nazari F. Mass immunity against diphtheria and tetanus in some urban and rural areas in Iran. Arch Inst Razi 1973; 49-55.
8. Nazari F, Mirchamsy H, Alé-Agha S, Mahinpour M. A model for developing countries of mass serological survey of children vaccinated against diphtheria and tetanus. J Biol Stand 1976; 4:329-35; PMID:993218; http://dx.doi.org/10.1016/S0092-1157(76)80017-0.
9. Zarei S, Jeddi-Tehrani M, Akhondi MM, Zeraati H, Pourheidari F, Ostadkarampour M, et al. Primary immunization with a triple diphtheria-tetanus- whole cell pertussis vaccine in Iranian infants: an analysis of antibody response. Iran J Allergy Asthma Immunol 2009; 8:85-93; PMID:19671937.
10. Launay O, Toneatti C, Bernède C, Njamkepo E, Petitprez K, Leblond A, et al. Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations. Hum Vaccin 2009; 5:341-6; PMID:19221513; http://dx.doi.org/10.4161/hv.5.5.7575.
11. Tansel O, Ekuklu G, Eker A, Kunduracilar H, Yulugkural Z, Yüksel P. Community-based seroepidemiology of diphtheria and tetanus in Edirne, Turkey. Jpn J Infect Dis 2009; 62:275-8; PMID:19628904.
12. CDC. Expanded program on immunization (EPI), Islamic republic of Iran, Immunization schedule. Tehran: Ministry of Health, Treatment and Medical Education of Iran, 2010.
13. Fletcher MA, Saliou P, Ethevenaux C, Plotkin SA. The efficacy of whole cell pertussis immunisation: collected data on a vaccine produced in France. Public Health 2001; 115:119-29; PMID:11406777.
14. World Health Organization. WHO position paper. Diphtheria vaccine. Weekly epidemiological record/Health Section of the Secretariat of the League of Nations 2006; 81:21-32.
15. Konda T, Kamachi K, Iwaki M, Matsunaga Y. Distribution of pertussis antibodies among different age groups in Japan. Vaccine 2002; 20:1711-7; PMID:11906757; http://dx.doi.org/10.1016/S0264-410X(02)00045-2.
16. Forsyth K, Nagai M, Lepetic A, Trindade E. Pertussis immunization in the global pertussis initiative international region: recommended strategies and implementation considerations. Pediatr Infect Dis J 2005; 24(Suppl):S93-7; PMID:15876935; http://dx.doi.org/10.1097/01.inf.0000160921.74004.12.
17. Van Damme P, Burgess M. Immunogenicity of a combined diphtheria-tetanus- acellular pertussis vaccine in adults. Vaccine 2004; 22:305-8; PMID:14670310; http://dx.doi.org/10.1016/j.vaccine.2003.08.012.
18. Hendrikx LH, Oztürk K, de Rond LG, Veenhoven RH, Sanders EA, Berbers GA, et al. Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins. Vaccine 2011; 29:1431-7; PMID:21187178; http://dx.doi.org/10.1016/j.vaccine.2010.12.033.
19. Kosuwon P, Warachit B, Hutagalung Y, Borkird T, Kosalaraksa P, Bock HL, et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine 2003; 21:4194-200; PMID:14505898; http://dx.doi.org/10.1016/S0264- 410X(03)00496-1.
20. Halperin SA, Scheifele D, Mills E, Guasparini R, Humphreys G, Barreto L, et al. Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a fivecomponent acellular pertussis-based combination vaccine. Vaccine 2003; 21:2298-306; PMID:12744860; http://dx.doi.org/10.1016/S0264-410X(03)00173-7.
21. Christy C, Pichichero ME, Reed GF, Decker MD, Anderson EL, Rennels MB, et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics 1995; 96:584-7; PMID:7659481.
22. Blennow M, Granström M, Jäätmaa E, Olin P. Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial. Pediatrics 1988; 82:293-9; PMID:3043367.
23. Poland GA, Jacobson RM. Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine 2001; 19:2440-5; PMID:11257375; http://dx.doi.org/10.1016/S0264-410X(00)00469-2.
24. Zarei S, Jeddi-Tehrani M, Zeraati H, Milanifar AR, Ramazankhani A, Shokri F. Short Term Reactogenicity of a Triple Diphtheria-Tetanus-Whole Cell Pertussis Vaccine in Iranian Infants. Iran J Public Health 2009; 38:100-11.